Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2022 | Challenges to be overcome in the use of ctDNA for colon cancer treatment

Julien Taieb • 29 Jun 2022
ESMO WCGIC 2022
Colon Cancer Gastrointestinal Cancer

Julien Taieb, MD, PhD, European Hospital Georges Pompidou, Paris, France, discusses the need for larger studies to confirm the use of circulating tumor DNA (ctDNA) as an indicator of minimal residual disease (MRD) in patients with colon cancer. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.

More from Julien Taieb

0:39
The future of ctDNA as an indicator of colorectal cancer recurrence at ESMO 2023
Julien Taieb • 20 Oct 2023
1:19
ctDNA as a biomarker for post-resection colorectal cancer recurrence
Julien Taieb • 20 Oct 2023
1:11
Advances in colorectal cancer therapies at ESMO 2023
Julien Taieb • 20 Oct 2023
0:33
BRAF testing in CRC: comprehensive approach across all stages, affordability, and global advocacy
Julien Taieb • 20 Oct 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals